First I see that GlaxoSmithKline (GSK) shares were nicely firm yesterday. As I noted here back in mid-February I could see an opportunity to buy the shares...which I did later on that month. Yesterday’s move was driven by an article - planted in the FT - which noted that "Hedge fund Elliott builds up multibillion-pound stake in GSK...Activist group’s investment comes as UK drugmaker's performance lags rivals".
Hello, Share Tasters. It’s been a while since I’ve looked at GlaxoSmithKline (GSK). It’s the big British rival of AstraZeneca (AZN). Though it’s lost out in the publicity stakes associated with a covid vaccine, Glaxo should still benefit from a heightened interest in all things medical.
I have not been a fan of GlaxoSmithKline (GSK) shares for a long time now but if you pick up its chart today, you will see the stock kicking around at a new five year low. So what to think about a name that used to be a FTSE 100 favourite...and is even actively trying to finalise a Covid-19 vaccine product?
Hello Share Chasers. Many of us will be trying out short-term plays on speculative shares in these volatile days. With shares up and down a lot, you may even be tempted into a bit of day trading. However, my 24-hour trades nearly always become long-term investments as the hoped for daily hike hardly ever happens. Not to me anyway. So let’s look at a share which, if held long enough, could be a strong winner...
Hello, Share Breakers. As I’ve suggested before, pharmaceutical companies, both gigantic and small, could benefit from the heightened interest in all health matters. And I would guess that the one that comes up with a vaccine for COVID-19 might do even better. So which companies are looking for a vaccine?...
Assuming that you aren’t just going to move entirely to cash and wait for the markets to bottom and show signs of a rebound before buying anything, there are still some options for shares to hold whilst you ride out the storm.
Hello, Share Dibbers. The jumbo pharma GlaxoSmithKline (GSK) is undergoing changes. And if you think the company is making the right decisions, then then you might consider a closer look. The City has been pleased with the latest quarter results and though my own holding has not risen much over the years, perhaps that could change now...
Hello Share Peekers. A Footsie jumbo which I have shares in, but rarely write about, is GlaxoSmithKline (GSK).To give you an idea of its size, it’s the fourth biggest outfit in the Footsie. And while it's true the big fish can flounder, like the former British Energy, for example, we can hope for a measure of security not inherent in smaller companies.
Hello Share Trudgers. Though treading in my erudite colleague Chris Bailey’s shoes, I thought it might be useful to have another take on GlaxoSmithKline (GSK) This giant pharma is a big part of my ‘safer’ Footsie portfolio (I put safer in quotes as some of my biggest losses ever have been members of the big 100 club)...
Hello, Share Whackers. My more inspirational Shareprophets colleague Chris Bailey has already posted on an exciting development for GlaxoSmithKline (GSK). As this is a share I’ve also pushed for some years, allow me to add my own humble thoughts...
Much has been said or written about GlaxoSmithKline (GSK) during 2018 and my most recent contribution back in July suggested that a divisional split-up was a spoof. Well today's announcement that Glaxo has formed a joint venture vehicle with US pharma behemoth Pfizer for their respective consumer health arms (with ownership split 68%/32% in favour of Glaxo) appears at face value like a step in the right direction for under pressure CEO Emma Walmsley and team…
Hello, Share Pinchers. One of the most attractive sectors to invest in for those who like to inhabit the moral high ground is medicine. Who would not want to try to alleviate pain and suffering in Britain and the world? Yes, there can be worries that some companies are not as good as they might be in curbing the costs of treatment and drugs, but on the whole it’s a satisfying area of investment.
Last week I hoped that GlaxoSmithKline's (GSK) backing away from a mega deal which would have seen them splurge US$20bn odd on the consumer unit of American pharma name Pfizer was an early sign of a new commitment to not building an empire and maybe even considering splitting the company up into its constituent parts. Well that slammed that door closed today with news that they are buying out the shares in a consumer healthcare jv they have with the Swiss pharma giant Novartis for a cool US$13 billion.
The Mail on Sunday headline says it all " Brexit fears are diverting cash from vital cancer battle say drug firms." That sod Boris Johnson and the witch Priti Patel - now they are causing more cancer patients to die. Bastards! Er....
